Regeneron Pharmaceuticals, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The focal point of the investigation revolves around the Company’s potential issuance of inaccurate or deceptive statements, as well as its alleged failure to divulge crucial information of significance to investors. On June 27, 2023, Regeneron received a response letter from the FDA, wherein the agency declined to grant approval for the Company’s application seeking an 8mg dosage of aflibercept, marketed as Eylea within the United States. Regeneron asserts that the denial is attributable to an ongoing assessment of findings pertaining to a third-party filler. Subsequently, upon the dissemination of this news, Regeneron’s shares experienced a decline surpassing 9% on the very same day.